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background:  Patients with chronic obstructive pulmonary disease (COPD) experiencing an acute coronary syndrome (ACS) are at high 
risk for clinical events. In the PLATO trial, ticagrelor reduced the composite endpoint of death from vascular causes, MI and stroke in 
ACS compared to clopidogrel but increased the incidence of dyspnea, which may lead clinicians to withhold ticagrelor from patients with 
COPD. The purpose of this PLATO analysis was to investigate the efficacy and safety of ticagrelor vs. clopidogrel in patients with ACS and 
concomitant COPD.
methods:  In 18,624 patients with ACS randomized to treatment with either ticagrelor or clopidogrel, history of COPD was recorded in 1085 
patients. Clinical outcomes at 12 months were evaluated.
Results:  Results of efficacy and safety endpoints as well as incidence of dyspnea are described in the table. No endpoint reached a 
p-value for interaction < 0.05, indicating that these subgroup results are consistent with the main PLATO findings.
Table. Association of treatment with endpoints.
Ticagrelor Clopidogrel HR (95% CI)
Primary efficacy endpoint:
Death from vascular causes, MI, stroke
COPD 77/555 (14.8) 101/530 (20.6) 0.72 (0.54-0.97)
No COPD 787/8770 (9.6) 913/8758 (11.1) 0.86 (0.78-0.94)
Myocardial infarction
COPD 45/555 (8.9) 56/530 (11.8) 0.76 (0.52-1.13)
No COPD 459/8770 (5.7) 537/8758 (6.6) 0.85 (0.75-0.96)
Death from vascular causes
COPD 35/555 (6.9) 52/530 (11.0) 0.65 (0.42-0.99)
No COPD 318/8770 (3.8) 390/8758 (4.8) 0.81 (0.70-0.94)
Death from any cause
COPD 43/555 (8.4) 59/530 (12.4) 0.70 (0.47-1.04)
No COPD 356/8770 (4.3) 447/8758 (5.6) 0.79 (0.69-0.91)
Primary safety endpoint:
Major bleeding, defined by study criteria
COPD 68/550 (14.6) 77/521 (16.6) 0.85 (0.61-1.17)
No COPD 893/8683 (11.4) 852/8665 (10.9) 1.05 (0.96-1.16)
Dyspnea, any episode
COPD 117/550 (26.1) 71/521 (16.3) 1.71 (1.28-2.30)
No COPD 1153/8683 (15.3) 650/8665 (8.9) 1.85 (1.68-2.04)
Dyspnea, episode requiring discontinuation of study drug
COPD 12/550 (2.5) 1/521 (0.2) --
No COPD 67/8683 (0.9) 12/8665 (0.2) --
conclusion:  COPD patients showed a higher ischemic event rate than non-COPD patients. They had similar efficacy benefit and safety 
profile of ticagrelor compared to clopidogrel as non-COPD patients. Overall dyspnea rates were higher in COPD patients, but the relative 
increase in the ticagrelor treated group was similar to the main study population. Discontinuation rate of ticagrelor due to dyspnea was low. 
This study supports the use of ticagrelor as an efficacious and safe treatment in patients with ACS and concomitant COPD.
